Anthony Y. Sun - Nov 1, 2021 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Signature
By: /s/ Melissa B. Epperly, Attorney-in-Fact for Anthony Y. Sun
Stock symbol
ZNTL
Transactions as of
Nov 1, 2021
Transactions value $
-$1,695,374
Form type
4
Date filed
11/2/2021, 07:24 PM
Previous filing
Oct 4, 2021
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$357K -4.42K -0.35% $80.72 1.27M Nov 1, 2021 Direct F1, F2
transaction ZNTL Common Stock Sale -$265K -3.25K -0.26% $81.48 1.26M Nov 1, 2021 Direct F1, F3
transaction ZNTL Common Stock Sale -$214K -2.6K -0.21% $82.49 1.26M Nov 1, 2021 Direct F1, F4
transaction ZNTL Common Stock Sale -$16.6K -200 -0.02% $83.19 1.26M Nov 1, 2021 Direct F1, F5
transaction ZNTL Common Stock Sale -$119K -1.49K -0.12% $79.40 1.26M Nov 2, 2021 Direct F1, F6
transaction ZNTL Common Stock Sale -$416K -5.18K -0.41% $80.32 1.25M Nov 2, 2021 Direct F1, F7
transaction ZNTL Common Stock Sale -$308K -3.8K -0.3% $81.10 1.25M Nov 2, 2021 Direct F1, F8
holding ZNTL Common Stock 974K Nov 1, 2021 By Essex Group International, LLC
holding ZNTL Common Stock 214K Nov 1, 2021 See Footnote F9
holding ZNTL Common Stock 229K Nov 1, 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.03 to $81.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $81.03 to $82.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $82.05 to $82.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $83.13 to $83.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.78 to $79.76. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $79.81 to $80.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.81 to $81.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F9 Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.